Loading...
XJPX4554
Market cap233mUSD
Jan 15, Last price  
1,503.00JPY
1D
-1.76%
1Q
14.47%
Jan 2017
11.33%
Name

Fuji Pharma Co Ltd

Chart & Performance

D1W1MN
XJPX:4554 chart
P/E
10.63
P/S
0.89
EPS
141.43
Div Yield, %
2.46%
Shrs. gr., 5y
-4.08%
Rev. gr., 5y
1.52%
Revenues
40.89b
+15.42%
14,940,538,00017,201,236,00019,701,956,00021,623,812,00021,522,065,00025,174,000,00029,215,000,00031,680,000,00034,229,000,00035,387,000,00037,909,000,00036,279,000,00033,793,000,00033,990,000,00035,426,000,00040,889,000,000
Net income
3.44b
+27.41%
1,251,714,0001,525,958,0001,944,071,0002,204,846,0001,370,930,0002,068,000,0002,078,000,0002,092,000,0002,118,000,0003,301,000,0003,372,000,0002,962,000,0002,085,000,0002,432,000,0002,696,000,0003,435,000,000
CFO
1.92b
P
952,631,0001,816,744,0002,168,237,0001,954,075,0001,171,679,0003,630,000,0002,757,000,000589,000,0004,509,000,0003,238,000,0003,773,000,0007,035,000,0005,770,000,0005,993,000,000-658,000,0001,917,000,000
Dividend
Mar 28, 20250 JPY/sh

Profile

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
URL
https://www.fujipharma.jp/
IPO date
Jun 22, 1995
Employees
1,560
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
40,889,000
15.42%
35,426,000
4.22%
Cost of revenue
27,558,000
23,352,000
Unusual Expense (Income)
NOPBT
13,331,000
12,074,000
NOPBT Margin
32.60%
34.08%
Operating Taxes
963,000
1,026,000
Tax Rate
7.22%
8.50%
NOPAT
12,368,000
11,048,000
Net income
3,435,000
27.41%
2,696,000
10.86%
Dividends
(899,000)
(729,000)
Dividend yield
3.17%
2.90%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
17,024,000
11,117,000
Long-term debt
15,679,000
16,088,000
Deferred revenue
(437,000)
Other long-term liabilities
2,461,000
2,308,000
Net debt
30,376,000
16,320,000
Cash flow
Cash from operating activities
1,917,000
(658,000)
CAPEX
(3,897,000)
(12,423,000)
Cash from investing activities
(5,240,000)
(11,271,000)
Cash from financing activities
1,915,000
5,094,000
FCF
4,379,000
2,319,000
Balance
Cash
2,324,000
3,546,000
Long term investments
3,000
7,339,000
Excess cash
282,550
9,113,700
Stockholders' equity
32,883,000
31,973,000
Invested Capital
72,302,450
52,685,300
ROIC
19.79%
25.56%
ROCE
18.37%
19.40%
EV
Common stock shares outstanding
24,301
24,293
Price
1,166.00
12.77%
1,034.00
-11.62%
Market cap
28,335,343
12.80%
25,119,114
-20.09%
EV
58,713,343
41,441,114
EBITDA
16,354,000
14,819,000
EV/EBITDA
3.59
2.80
Interest
121,000
77,000
Interest/NOPBT
0.91%
0.64%